Rituximab, Bendamustine and Cytarabine Followed by Venetoclax (V-RBAC) in High-risk Elderly Patients With Mantle Cell Lymphoma (MCL)
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2019
Price : $35 *
At a glance
- Drugs Venetoclax (Primary) ; Bendamustine; Cytarabine; Rituximab
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 15 Jan 2019 Status changed from not yet recruiting to recruiting.
- 06 Jul 2018 Planned End Date changed from 1 Jun 2025 to 1 Jul 2025.
- 06 Jul 2018 Planned primary completion date changed from 1 Jun 2020 to 1 Jul 2020.